Teleflex Incorporated (TFX) 10-Year Financial Performance & Capital Metrics

TFX • • Industrial / General

HealthcareMedical InstrumentsInfusion & Drug Delivery SystemsIV Therapy & Access Products

AboutTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.Show more

Revenue $3.05B +2.4%
EBITDA $426M -43.1%
Net Income $70M -80.4%
EPS (Diluted) 1.48 -80.3%
Gross Margin 55.87% +0.9%
EBITDA Margin 13.97% -44.5%
Operating Margin 4.96% -70.9%
Net Margin 2.29% -80.9%
ROE 1.6% -81.0%
ROIC 1.91% -70.6%
Debt/Equity 0.41 -5.4%
Interest Coverage 1.81 -69.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 16.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 11.6%
✓Trading at only 1.2x book value

✗Weaknesses

✗Profits declining 31.5% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.18%

5Y3.26%

3Y2.74%

TTM5.43%

Profit (Net Income) CAGR

10Y-9.43%

5Y-31.48%

3Y-47.64%

TTM-238.13%

EPS CAGR

10Y-9.55%

5Y-31.48%

3Y-47.5%

TTM-246.12%

ROCE

10Y Avg7.5%

5Y Avg6.9%

3Y Avg5.95%

Latest2.26%

Peer Comparison

IV Therapy & Access Products

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TFXTeleflex Incorporated	4.62B	104.61	70.68	2.45%	-10.28%	-8.58%	11.02%	0.41
HAEHaemonetics Corporation	3.46B	74.00	22.36	3.95%	12.67%	19.81%	4.11%	1.49
ICUIICU Medical, Inc.	3.83B	155.12	-32.12	5.44%	-0.32%	-0.35%	3.26%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.81B	1.87B	2.15B	2.45B	2.6B	2.54B	2.81B	2.79B	2.97B	3.05B
Revenue Growth %	-0.02%	0.03%	0.15%	0.14%	0.06%	-0.02%	0.11%	-0.01%	0.07%	0.02%
Cost of Goods Sold+	865.29M	871.83M	974.5M	1.06B	1.19B	1.21B	1.26B	1.26B	1.33B	1.34B
COGS % of Revenue	0.48%	0.47%	0.45%	0.43%	0.46%	0.48%	0.45%	0.45%	0.45%	0.44%
Gross Profit+	944.4M	996.2M	1.17B	1.38B	1.41B	1.32B	1.55B	1.53B	1.65B	1.7B
Gross Margin %	0.52%	0.53%	0.55%	0.57%	0.54%	0.52%	0.55%	0.55%	0.55%	0.56%
Gross Profit Growth %	0%	0.05%	0.18%	0.18%	0.02%	-0.06%	0.17%	-0.01%	0.08%	0.03%
Operating Expenses+	621.1M	621.89M	784.73M	984.9M	981.75M	901.81M	921.51M	1.03B	1.14B	1.55B
OpEx % of Revenue	0.34%	0.33%	0.37%	0.4%	0.38%	0.36%	0.33%	0.37%	0.38%	0.51%
Selling, General & Admin	568.98M	563.31M	699.96M	878.69M	851.77M	743.57M	860.09M	863.75M	929.87M	995.27M
SG&A % of Revenue	0.31%	0.3%	0.33%	0.36%	0.33%	0.29%	0.31%	0.31%	0.31%	0.33%
Research & Development	52.12M	58.58M	84.77M	106.21M	113.86M	119.75M	130.84M	153.82M	154.35M	161.67M
R&D % of Revenue	0.03%	0.03%	0.04%	0.04%	0.04%	0.05%	0.05%	0.06%	0.05%	0.05%
Other Operating Expenses	0	0	0	0	16.13M	38.49M	-69.42M	13.79M	56.4M	394.72M
Operating Income+	315.89M	319.45M	372.28M	321.7M	427.25M	423.07M	628.1M	499.73M	506.31M	151.01M
Operating Margin %	0.17%	0.17%	0.17%	0.13%	0.16%	0.17%	0.22%	0.18%	0.17%	0.05%
Operating Income Growth %	0.11%	0.01%	0.17%	-0.14%	0.33%	-0.01%	0.48%	-0.2%	0.01%	-0.7%
EBITDA+	424.28M	437.36M	527.54M	531.68M	641.32M	650.32M	865.46M	730.32M	748.43M	425.61M
EBITDA Margin %	0.23%	0.23%	0.25%	0.22%	0.25%	0.26%	0.31%	0.26%	0.25%	0.14%
EBITDA Growth %	0.07%	0.03%	0.21%	0.01%	0.21%	0.01%	0.33%	-0.16%	0.02%	-0.43%
D&A (Non-Cash Add-back)	108.39M	117.91M	155.26M	209.98M	214.06M	227.25M	237.36M	230.59M	242.12M	274.6M
EBIT	305.97M	300.67M	367.46M	322.65M	420.17M	424.23M	616.44M	500.18M	519.09M	159.02M
Net Interest Income+	-60.79M	-54.47M	-81.78M	-102.08M	-78.53M	-65.34M	-55.64M	-53.35M	-72.3M	-75.53M
Interest Income	532K	474K	771K	944K	1.74M	1.16M	1.33M	912K	12.78M	8.01M
Interest Expense	61.32M	54.94M	82.55M	103.02M	80.27M	66.49M	56.97M	54.26M	85.08M	83.54M
Other Income/Expense	-71.25M	-73.73M	-87.37M	23.2M	-87.35M	-65.34M	-68.63M	-53.81M	-72.3M	-75.53M
Pretax Income+	244.65M	245.72M	284.91M	219.63M	339.9M	357.73M	559.47M	445.92M	434.01M	75.48M
Pretax Margin %	0.14%	0.13%	0.13%	0.09%	0.13%	0.14%	0.2%	0.16%	0.15%	0.02%
Income Tax+	7.84M	8.07M	129.65M	23.2M	-122.08M	21.93M	74.35M	83M	76.44M	5.32M
Effective Tax Rate %	1%	0.97%	0.54%	0.91%	1.36%	0.94%	0.87%	0.81%	0.82%	0.92%
Net Income+	244.86M	237.38M	152.53M	200.8M	461.47M	335.32M	485.37M	363.14M	356.33M	69.67M
Net Margin %	0.14%	0.13%	0.07%	0.08%	0.18%	0.13%	0.17%	0.13%	0.12%	0.02%
Net Income Growth %	0.3%	-0.03%	-0.36%	0.32%	1.3%	-0.27%	0.45%	-0.25%	-0.02%	-0.8%
Net Income (Continuing)	236.81M	237.65M	155.26M	196.43M	461.98M	335.8M	485.12M	362.92M	357.57M	70.16M
Discontinued Operations	8.9M	190K	0	4.37M	-515K	-477K	255K	223K	-1.24M	-487K
Minority Interest	1.82M	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	5.10	4.98	3.27	4.29	9.80	7.09	10.23	7.68	7.53	1.48
EPS Growth %	0.26%	-0.02%	-0.34%	0.31%	1.28%	-0.28%	0.44%	-0.25%	-0.02%	-0.8%
EPS (Basic)	5.89	5.48	3.39	4.39	9.99	7.21	10.38	7.74	7.58	1.49
Diluted Shares Outstanding	48.06M	47.65M	46.66M	46.8M	47.09M	47.29M	47.43M	47.31M	47.3M	47.09M
Basic Shares Outstanding	41.56M	43.33M	45M	45.69M	46.2M	46.49M	46.77M	46.9M	46.98M	46.84M
Dividend Payout Ratio	0.23%	0.25%	0.4%	0.31%	0.14%	0.19%	0.13%	0.18%	0.18%	0.91%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.01B	1.18B	1.13B	1.24B	1.31B	1.42B	1.43B	1.41B	1.41B	1.47B
Cash & Short-Term Investments	338.37M	543.79M	333.56M	357.16M	301.08M	375.88M	445.08M	292.03M	222.85M	306.16M
Cash Only	338.37M	543.79M	333.56M	357.16M	301.08M	375.88M	445.08M	292.03M	222.85M	290.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	15.97M
Accounts Receivable	262.42M	271.99M	345.88M	366.29M	418.67M	395.07M	383.57M	408.83M	443.47M	459.5M
Days Sales Outstanding	52.93	53.15	58.82	54.61	58.88	56.84	49.83	53.47	54.42	55.04
Inventory	330.27M	316.17M	395.74M	427.78M	476.56M	513.2M	477.64M	578.51M	626.22M	600.13M
Days Inventory Outstanding	139.32	132.37	148.23	146.76	146.62	154.52	138.37	167.59	172.17	162.9
Other Current Assets	41.89M	43.26M	47.88M	72.48M	97.94M	115.44M	117.28M	125.08M	107.47M	101.88M
Total Non-Current Assets+	2.87B	2.71B	5.05B	5.04B	5B	5.73B	5.44B	5.52B	6.13B	5.63B
Property, Plant & Equipment	316.12M	302.9M	383M	432.77M	543.88M	574.55M	573.41M	578.42M	603.43M	611.76M
Fixed Asset Turnover	5.72x	6.17x	5.60x	5.66x	4.77x	4.42x	4.90x	4.83x	4.93x	4.98x
Goodwill	1.3B	1.28B	2.24B	2.25B	2.25B	2.59B	2.5B	2.54B	2.91B	2.63B
Intangible Assets	1.2B	1.09B	2.38B	2.33B	2.16B	2.52B	2.29B	2.31B	2.5B	2.27B
Long-Term Investments	152K	2.7M	3.3M	2.7M	0	0	0	11.91M	0	0
Other Non-Current Assets	57.64M	32.13M	43.24M	32.28M	52.45M	41.8M	69.1M	77.45M	98.94M	102.62M
Total Assets+	3.88B	3.89B	6.18B	6.28B	6.31B	7.15B	6.87B	6.93B	7.53B	7.1B
Asset Turnover	0.47x	0.48x	0.35x	0.39x	0.41x	0.35x	0.41x	0.40x	0.39x	0.43x
Asset Growth %	-0.02%	0%	0.59%	0.02%	0.01%	0.13%	-0.04%	0.01%	0.09%	-0.06%
Total Current Liabilities+	666.71M	427.65M	483.88M	582.46M	563.05M	540.03M	680.12M	581.49M	606.75M	649.36M
Accounts Payable	66.31M	69.4M	92.03M	106.71M	102.92M	102.52M	118.24M	126.81M	132.25M	141.03M
Days Payables Outstanding	27.97	29.06	34.47	36.61	31.66	30.87	34.25	36.74	36.36	38.28
Short-Term Debt	417.35M	183.07M	86.63M	86.63M	50M	100.5M	110M	87.5M	87.5M	100M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	87.75M	84.59M	186.29M	278.51M	181.49M	53.87M	55.63M	63.38M	46.55M	68.54M
Current Ratio	1.51x	2.77x	2.33x	2.12x	2.32x	2.63x	2.10x	2.43x	2.32x	2.27x
Quick Ratio	1.01x	2.03x	1.51x	1.39x	1.47x	1.68x	1.40x	1.43x	1.29x	1.34x
Cash Conversion Cycle	164.28	156.46	172.58	164.75	173.84	180.48	153.95	184.32	190.23	179.66
Total Non-Current Liabilities+	1.2B	1.32B	3.27B	3.16B	2.77B	3.28B	2.44B	2.32B	2.48B	2.17B
Long-Term Debt	641.85M	850.25M	2.16B	2.07B	1.86B	2.38B	1.74B	1.62B	1.73B	1.56B
Capital Lease Obligations	0	0	0	0	101.37M	86.1M	116.03M	120.44M	111.3M	99.15M
Deferred Tax Liabilities	315.98M	271.38M	603.68M	608.22M	439.56M	484.68M	370.12M	388.89M	456.08M	391.07M
Other Non-Current Liabilities	238.73M	202.6M	500.48M	475.14M	367.57M	327.41M	210.6M	191.26M	189.86M	124.32M
Total Liabilities	1.87B	1.75B	3.75B	3.74B	3.33B	3.82B	3.12B	2.91B	3.09B	2.82B
Total Debt+	1.07B	1.03B	2.25B	2.16B	2.01B	2.56B	1.97B	1.83B	1.93B	1.76B
Net Debt	727.58M	489.53M	1.92B	1.8B	1.71B	2.19B	1.52B	1.54B	1.7B	1.46B
Debt / Equity	0.53x	0.48x	0.93x	0.85x	0.67x	0.77x	0.52x	0.46x	0.43x	0.41x
Debt / EBITDA	2.51x	2.36x	4.26x	4.06x	3.13x	3.94x	2.27x	2.51x	2.57x	4.12x
Net Debt / EBITDA	1.71x	1.12x	3.63x	3.39x	2.67x	3.37x	1.76x	2.11x	2.28x	3.44x
Interest Coverage	5.15x	5.81x	4.51x	3.12x	5.32x	6.36x	11.03x	9.21x	5.95x	1.81x
Total Equity+	2.01B	2.14B	2.43B	2.54B	2.98B	3.34B	3.75B	4.02B	4.44B	4.28B
Equity Growth %	0.05%	0.06%	0.14%	0.05%	0.17%	0.12%	0.13%	0.07%	0.1%	-0.04%
Book Value per Share	41.85	44.90	52.09	54.27	63.27	70.56	79.17	85.01	93.88	90.84
Total Shareholders' Equity	2.01B	2.14B	2.43B	2.54B	2.98B	3.34B	3.75B	4.02B	4.44B	4.28B
Common Stock	43.52M	45.81M	46.87M	47.25M	47.54M	47.81M	47.93M	47.96M	48.05M	48.1M
Retained Earnings	2.02B	2.19B	2.29B	2.43B	2.82B	3.1B	3.52B	3.82B	4.11B	4.12B
Treasury Stock	-119.42M	-170.97M	-228.86M	-168.54M	-165.72M	-162.59M	-157.27M	-154.89M	-152.1M	-350.34M
Accumulated OCI	-371.12M	-438.72M	-265.09M	-341.08M	-344.39M	-297.3M	-346.96M	-403.52M	-314.4M	-316.67M
Minority Interest	1.82M	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	300.81M	408.48M	419.88M	437.38M	439.52M	436.41M	651.42M	342.14M	510.64M	635.74M
Operating CF Margin %	0.17%	0.22%	0.2%	0.18%	0.17%	0.17%	0.23%	0.12%	0.17%	0.21%
Operating CF Growth %	0.05%	0.36%	0.03%	0.04%	0%	-0.01%	0.49%	-0.47%	0.49%	0.24%
Net Income	245.71M	237.84M	152.53M	200.8M	461.47M	335.32M	485.37M	363.14M	356.33M	69.67M
Depreciation & Amortization	108.39M	117.91M	155.26M	209.98M	214.06M	227.25M	237.36M	230.59M	242.12M	274.6M
Stock-Based Compensation	14.47M	16.87M	19.41M	22.44M	26.94M	20.74M	22.94M	27.22M	31.46M	31.35M
Deferred Taxes	-54.41M	-29.35M	-41.82M	-6.1M	-168.59M	-32.67M	-110.24M	-13.01M	-13.05M	0
Other Non-Cash Items	-9.9M	46.63M	2.53M	54.55M	20.15M	-136.51M	-111.36M	-25.84M	5.54M	261.94M
Working Capital Changes	-3.44M	18.57M	131.97M	-44.3M	-114.5M	22.28M	127.34M	-239.96M	-111.77M	-1.82M
Change in Receivables	398K	-11.03M	-11.04M	-23.41M	-59.79M	44.75M	-600K	-38.46M	-15.76M	-27.95M
Change in Inventory	-8.37M	6.41M	-22.36M	-37.2M	-53.17M	-5.5M	-11.14M	-110.69M	-41.07M	1.72M
Change in Payables	-117K	15.42M	39M	52.05M	5M	-3.68M	94.02M	-24.79M	-31.26M	9.66M
Cash from Investing+	-154.85M	-56.97M	-1.83B	-196.39M	-73.48M	-837.78M	156.74M	-257.94M	-621.23M	-99.36M
Capital Expenditures	-61.45M	-53.13M	-70.9M	-80.8M	-102.69M	-90.69M	-71.62M	-79.19M	-91.44M	-126.43M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.04%	0.04%	0.03%	0.03%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	408K	10.2M	6.33M	1.55M	18.33M	19.34M	19.15M	22.24M	63.13M	27.2M
Cash from Financing+	-85.58M	-118.69M	1.14B	-206.43M	-418.84M	455.16M	-715.82M	-217.51M	38.54M	-421.93M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-56.53M	-58.96M	-61.24M	-62.16M	-62.83M	-63.22M	-63.65M	-63.79M	-63.9M	-63.54M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-13.39M	-16.87M	-21.43M	-50.77M	-102.51M	-56.62M	-28.77M	-8.27M	1.19M	3.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	239.36M	355.35M	348.98M	356.58M	336.83M	345.71M	579.8M	262.95M	419.2M	509.31M
FCF Margin %	0.13%	0.19%	0.16%	0.15%	0.13%	0.14%	0.21%	0.09%	0.14%	0.17%
FCF Growth %	0.09%	0.48%	-0.02%	0.02%	-0.06%	0.03%	0.68%	-0.55%	0.59%	0.21%
FCF per Share	4.98	7.46	7.48	7.62	7.15	7.31	12.23	5.56	8.86	10.81
FCF Conversion (FCF/Net Income)	1.23x	1.72x	2.75x	2.18x	0.95x	1.30x	1.34x	0.94x	1.43x	9.12x
Interest Paid	45.97M	44.2M	74.26M	101.79M	0	0	73.6M	70.92M	100.22M	98.38M
Taxes Paid	56.08M	23.95M	49.14M	65.61M	0	0	108.61M	162.05M	114.21M	164.9M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	12.48%	11.44%	6.68%	8.08%	16.72%	10.62%	13.69%	9.34%	8.42%	1.6%
Return on Invested Capital (ROIC)	8.75%	8.93%	8.01%	5.55%	7.1%	6.21%	8.72%	6.92%	6.49%	1.91%
Gross Margin	52.19%	53.33%	54.6%	56.55%	54.29%	52.22%	55.15%	54.86%	55.37%	55.87%
Net Margin	13.53%	12.71%	7.11%	8.2%	17.78%	13.22%	17.28%	13.01%	11.98%	2.29%
Debt / Equity	0.53x	0.48x	0.93x	0.85x	0.67x	0.77x	0.52x	0.46x	0.43x	0.41x
Interest Coverage	5.15x	5.81x	4.51x	3.12x	5.32x	6.36x	11.03x	9.21x	5.95x	1.81x
FCF Conversion	1.23x	1.72x	2.75x	2.18x	0.95x	1.30x	1.34x	0.94x	1.43x	9.12x
Revenue Growth	-1.64%	3.22%	14.9%	14.07%	6%	-2.24%	10.74%	-0.66%	6.57%	2.45%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Vascular Access	-	-	-	575.33M	600.87M	657.7M	700.24M	683.61M	708.04M	732.67M
Vascular Access Growth	-	-	-	-	4.44%	9.46%	6.47%	-2.37%	3.57%	3.48%
Interventional	-	-	-	395.42M	427.56M	382.44M	427.5M	445.02M	511.43M	586.06M
Interventional Growth	-	-	-	-	8.13%	-10.55%	11.78%	4.10%	14.92%	14.59%
Surgical	-	-	-	358.71M	370.07M	317.2M	377.76M	392.92M	427.36M	450.48M
Surgical Growth	-	-	-	-	3.17%	-14.29%	19.09%	4.01%	8.77%	5.41%
Anesthesia	-	-	-	349.37M	338.41M	302.29M	380.14M	388.89M	389.96M	395.29M
Anesthesia Growth	-	-	-	-	-3.14%	-10.67%	25.75%	2.30%	0.27%	1.37%
Interventional Urology	-	-	-	196.74M	290.45M	290.02M	341.66M	322.83M	319.79M	331.09M
Interventional Urology Growth	-	-	-	-	47.63%	-0.15%	17.81%	-5.51%	-0.94%	3.54%
Other	218.66M	225.21M	233.98M	366.85M	347.27M	367.26M	336.58M	285.15M	291.9M	207.22M
Other Growth	-	3.00%	3.90%	56.79%	-5.34%	5.75%	-8.35%	-15.28%	2.37%	-29.01%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	1.47B	1.66B	1.65B	1.72B	1.89B
Americas Growth	-	-	-	-	-	-	13.26%	-0.34%	3.73%	10.14%
EMEA	514.44M	510.93M	552.72M	603.81M	652.07M	584.86M	606.81M	558.37M	586.25M	705.09M
EMEA Growth	-	-0.68%	8.18%	9.24%	7.99%	-10.31%	3.75%	-7.98%	4.99%	20.27%
Asia	241.73M	249.42M	269.21M	286.89M	241.28M	267.02M	297.77M	306.32M	346.9M	326.37M
Asia Growth	-	3.18%	7.94%	6.57%	-15.90%	10.67%	11.52%	2.87%	13.25%	-5.92%
Oem	149.4M	160.99M	182.97M	205.98M	-	220.25M	245.68M	272.62M	326.01M	-
Oem Growth	-	7.76%	13.65%	12.58%	-	-	11.55%	10.97%	19.58%	-
UNITED STATES	-	-	-	-	1.61B	-	-	-	-	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Teleflex Incorporated (TFX) has a price-to-earnings (P/E) ratio of 70.7x. This suggests investors expect higher future growth.

Growth & Financials

Teleflex Incorporated (TFX) reported $3.19B in revenue for fiscal year 2024. This represents a 109% increase from $1.53B in 2011.

Teleflex Incorporated (TFX) grew revenue by 2.4% over the past year. Growth has been modest.

Teleflex Incorporated (TFX) reported a net loss of $328.0M for fiscal year 2024.

Dividend & Returns

Yes, Teleflex Incorporated (TFX) pays a dividend with a yield of 1.29%. This makes it attractive for income-focused investors.

Teleflex Incorporated (TFX) has a return on equity (ROE) of 1.6%. This is below average, suggesting room for improvement.

Teleflex Incorporated (TFX) generated $264.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Teleflex Incorporated (TFX) 10-Year Financial Performance & Capital Metrics

TFX • • Industrial / General

HealthcareMedical InstrumentsInfusion & Drug Delivery SystemsIV Therapy & Access Products

Revenue $3.05B +2.4%
EBITDA $426M -43.1%
Net Income $70M -80.4%
EPS (Diluted) 1.48 -80.3%
Gross Margin 55.87% +0.9%
EBITDA Margin 13.97% -44.5%
Operating Margin 4.96% -70.9%
Net Margin 2.29% -80.9%
ROE 1.6% -81.0%
ROIC 1.91% -70.6%
Debt/Equity 0.41 -5.4%
Interest Coverage 1.81 -69.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 16.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 11.6%
✓Trading at only 1.2x book value

✗Weaknesses

✗Profits declining 31.5% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.18%

5Y3.26%

3Y2.74%

TTM5.43%

Profit (Net Income) CAGR

10Y-9.43%

5Y-31.48%

3Y-47.64%

TTM-238.13%

EPS CAGR

10Y-9.55%

5Y-31.48%

3Y-47.5%

TTM-246.12%

ROCE

10Y Avg7.5%

5Y Avg6.9%

3Y Avg5.95%

Latest2.26%

Peer Comparison

IV Therapy & Access Products

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TFXTeleflex Incorporated	4.62B	104.61	70.68	2.45%	-10.28%	-8.58%	11.02%	0.41
HAEHaemonetics Corporation	3.46B	74.00	22.36	3.95%	12.67%	19.81%	4.11%	1.49
ICUIICU Medical, Inc.	3.83B	155.12	-32.12	5.44%	-0.32%	-0.35%	3.26%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.81B	1.87B	2.15B	2.45B	2.6B	2.54B	2.81B	2.79B	2.97B	3.05B
Revenue Growth %	-0.02%	0.03%	0.15%	0.14%	0.06%	-0.02%	0.11%	-0.01%	0.07%	0.02%
Cost of Goods Sold+	865.29M	871.83M	974.5M	1.06B	1.19B	1.21B	1.26B	1.26B	1.33B	1.34B
COGS % of Revenue	0.48%	0.47%	0.45%	0.43%	0.46%	0.48%	0.45%	0.45%	0.45%	0.44%
Gross Profit+	944.4M	996.2M	1.17B	1.38B	1.41B	1.32B	1.55B	1.53B	1.65B	1.7B
Gross Margin %	0.52%	0.53%	0.55%	0.57%	0.54%	0.52%	0.55%	0.55%	0.55%	0.56%
Gross Profit Growth %	0%	0.05%	0.18%	0.18%	0.02%	-0.06%	0.17%	-0.01%	0.08%	0.03%
Operating Expenses+	621.1M	621.89M	784.73M	984.9M	981.75M	901.81M	921.51M	1.03B	1.14B	1.55B
OpEx % of Revenue	0.34%	0.33%	0.37%	0.4%	0.38%	0.36%	0.33%	0.37%	0.38%	0.51%
Selling, General & Admin	568.98M	563.31M	699.96M	878.69M	851.77M	743.57M	860.09M	863.75M	929.87M	995.27M
SG&A % of Revenue	0.31%	0.3%	0.33%	0.36%	0.33%	0.29%	0.31%	0.31%	0.31%	0.33%
Research & Development	52.12M	58.58M	84.77M	106.21M	113.86M	119.75M	130.84M	153.82M	154.35M	161.67M
R&D % of Revenue	0.03%	0.03%	0.04%	0.04%	0.04%	0.05%	0.05%	0.06%	0.05%	0.05%
Other Operating Expenses	0	0	0	0	16.13M	38.49M	-69.42M	13.79M	56.4M	394.72M
Operating Income+	315.89M	319.45M	372.28M	321.7M	427.25M	423.07M	628.1M	499.73M	506.31M	151.01M
Operating Margin %	0.17%	0.17%	0.17%	0.13%	0.16%	0.17%	0.22%	0.18%	0.17%	0.05%
Operating Income Growth %	0.11%	0.01%	0.17%	-0.14%	0.33%	-0.01%	0.48%	-0.2%	0.01%	-0.7%
EBITDA+	424.28M	437.36M	527.54M	531.68M	641.32M	650.32M	865.46M	730.32M	748.43M	425.61M
EBITDA Margin %	0.23%	0.23%	0.25%	0.22%	0.25%	0.26%	0.31%	0.26%	0.25%	0.14%
EBITDA Growth %	0.07%	0.03%	0.21%	0.01%	0.21%	0.01%	0.33%	-0.16%	0.02%	-0.43%
D&A (Non-Cash Add-back)	108.39M	117.91M	155.26M	209.98M	214.06M	227.25M	237.36M	230.59M	242.12M	274.6M
EBIT	305.97M	300.67M	367.46M	322.65M	420.17M	424.23M	616.44M	500.18M	519.09M	159.02M
Net Interest Income+	-60.79M	-54.47M	-81.78M	-102.08M	-78.53M	-65.34M	-55.64M	-53.35M	-72.3M	-75.53M
Interest Income	532K	474K	771K	944K	1.74M	1.16M	1.33M	912K	12.78M	8.01M
Interest Expense	61.32M	54.94M	82.55M	103.02M	80.27M	66.49M	56.97M	54.26M	85.08M	83.54M
Other Income/Expense	-71.25M	-73.73M	-87.37M	23.2M	-87.35M	-65.34M	-68.63M	-53.81M	-72.3M	-75.53M
Pretax Income+	244.65M	245.72M	284.91M	219.63M	339.9M	357.73M	559.47M	445.92M	434.01M	75.48M
Pretax Margin %	0.14%	0.13%	0.13%	0.09%	0.13%	0.14%	0.2%	0.16%	0.15%	0.02%
Income Tax+	7.84M	8.07M	129.65M	23.2M	-122.08M	21.93M	74.35M	83M	76.44M	5.32M
Effective Tax Rate %	1%	0.97%	0.54%	0.91%	1.36%	0.94%	0.87%	0.81%	0.82%	0.92%
Net Income+	244.86M	237.38M	152.53M	200.8M	461.47M	335.32M	485.37M	363.14M	356.33M	69.67M
Net Margin %	0.14%	0.13%	0.07%	0.08%	0.18%	0.13%	0.17%	0.13%	0.12%	0.02%
Net Income Growth %	0.3%	-0.03%	-0.36%	0.32%	1.3%	-0.27%	0.45%	-0.25%	-0.02%	-0.8%
Net Income (Continuing)	236.81M	237.65M	155.26M	196.43M	461.98M	335.8M	485.12M	362.92M	357.57M	70.16M
Discontinued Operations	8.9M	190K	0	4.37M	-515K	-477K	255K	223K	-1.24M	-487K
Minority Interest	1.82M	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	5.10	4.98	3.27	4.29	9.80	7.09	10.23	7.68	7.53	1.48
EPS Growth %	0.26%	-0.02%	-0.34%	0.31%	1.28%	-0.28%	0.44%	-0.25%	-0.02%	-0.8%
EPS (Basic)	5.89	5.48	3.39	4.39	9.99	7.21	10.38	7.74	7.58	1.49
Diluted Shares Outstanding	48.06M	47.65M	46.66M	46.8M	47.09M	47.29M	47.43M	47.31M	47.3M	47.09M
Basic Shares Outstanding	41.56M	43.33M	45M	45.69M	46.2M	46.49M	46.77M	46.9M	46.98M	46.84M
Dividend Payout Ratio	0.23%	0.25%	0.4%	0.31%	0.14%	0.19%	0.13%	0.18%	0.18%	0.91%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.01B	1.18B	1.13B	1.24B	1.31B	1.42B	1.43B	1.41B	1.41B	1.47B
Cash & Short-Term Investments	338.37M	543.79M	333.56M	357.16M	301.08M	375.88M	445.08M	292.03M	222.85M	306.16M
Cash Only	338.37M	543.79M	333.56M	357.16M	301.08M	375.88M	445.08M	292.03M	222.85M	290.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	15.97M
Accounts Receivable	262.42M	271.99M	345.88M	366.29M	418.67M	395.07M	383.57M	408.83M	443.47M	459.5M
Days Sales Outstanding	52.93	53.15	58.82	54.61	58.88	56.84	49.83	53.47	54.42	55.04
Inventory	330.27M	316.17M	395.74M	427.78M	476.56M	513.2M	477.64M	578.51M	626.22M	600.13M
Days Inventory Outstanding	139.32	132.37	148.23	146.76	146.62	154.52	138.37	167.59	172.17	162.9
Other Current Assets	41.89M	43.26M	47.88M	72.48M	97.94M	115.44M	117.28M	125.08M	107.47M	101.88M
Total Non-Current Assets+	2.87B	2.71B	5.05B	5.04B	5B	5.73B	5.44B	5.52B	6.13B	5.63B
Property, Plant & Equipment	316.12M	302.9M	383M	432.77M	543.88M	574.55M	573.41M	578.42M	603.43M	611.76M
Fixed Asset Turnover	5.72x	6.17x	5.60x	5.66x	4.77x	4.42x	4.90x	4.83x	4.93x	4.98x
Goodwill	1.3B	1.28B	2.24B	2.25B	2.25B	2.59B	2.5B	2.54B	2.91B	2.63B
Intangible Assets	1.2B	1.09B	2.38B	2.33B	2.16B	2.52B	2.29B	2.31B	2.5B	2.27B
Long-Term Investments	152K	2.7M	3.3M	2.7M	0	0	0	11.91M	0	0
Other Non-Current Assets	57.64M	32.13M	43.24M	32.28M	52.45M	41.8M	69.1M	77.45M	98.94M	102.62M
Total Assets+	3.88B	3.89B	6.18B	6.28B	6.31B	7.15B	6.87B	6.93B	7.53B	7.1B
Asset Turnover	0.47x	0.48x	0.35x	0.39x	0.41x	0.35x	0.41x	0.40x	0.39x	0.43x
Asset Growth %	-0.02%	0%	0.59%	0.02%	0.01%	0.13%	-0.04%	0.01%	0.09%	-0.06%
Total Current Liabilities+	666.71M	427.65M	483.88M	582.46M	563.05M	540.03M	680.12M	581.49M	606.75M	649.36M
Accounts Payable	66.31M	69.4M	92.03M	106.71M	102.92M	102.52M	118.24M	126.81M	132.25M	141.03M
Days Payables Outstanding	27.97	29.06	34.47	36.61	31.66	30.87	34.25	36.74	36.36	38.28
Short-Term Debt	417.35M	183.07M	86.63M	86.63M	50M	100.5M	110M	87.5M	87.5M	100M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	87.75M	84.59M	186.29M	278.51M	181.49M	53.87M	55.63M	63.38M	46.55M	68.54M
Current Ratio	1.51x	2.77x	2.33x	2.12x	2.32x	2.63x	2.10x	2.43x	2.32x	2.27x
Quick Ratio	1.01x	2.03x	1.51x	1.39x	1.47x	1.68x	1.40x	1.43x	1.29x	1.34x
Cash Conversion Cycle	164.28	156.46	172.58	164.75	173.84	180.48	153.95	184.32	190.23	179.66
Total Non-Current Liabilities+	1.2B	1.32B	3.27B	3.16B	2.77B	3.28B	2.44B	2.32B	2.48B	2.17B
Long-Term Debt	641.85M	850.25M	2.16B	2.07B	1.86B	2.38B	1.74B	1.62B	1.73B	1.56B
Capital Lease Obligations	0	0	0	0	101.37M	86.1M	116.03M	120.44M	111.3M	99.15M
Deferred Tax Liabilities	315.98M	271.38M	603.68M	608.22M	439.56M	484.68M	370.12M	388.89M	456.08M	391.07M
Other Non-Current Liabilities	238.73M	202.6M	500.48M	475.14M	367.57M	327.41M	210.6M	191.26M	189.86M	124.32M
Total Liabilities	1.87B	1.75B	3.75B	3.74B	3.33B	3.82B	3.12B	2.91B	3.09B	2.82B
Total Debt+	1.07B	1.03B	2.25B	2.16B	2.01B	2.56B	1.97B	1.83B	1.93B	1.76B
Net Debt	727.58M	489.53M	1.92B	1.8B	1.71B	2.19B	1.52B	1.54B	1.7B	1.46B
Debt / Equity	0.53x	0.48x	0.93x	0.85x	0.67x	0.77x	0.52x	0.46x	0.43x	0.41x
Debt / EBITDA	2.51x	2.36x	4.26x	4.06x	3.13x	3.94x	2.27x	2.51x	2.57x	4.12x
Net Debt / EBITDA	1.71x	1.12x	3.63x	3.39x	2.67x	3.37x	1.76x	2.11x	2.28x	3.44x
Interest Coverage	5.15x	5.81x	4.51x	3.12x	5.32x	6.36x	11.03x	9.21x	5.95x	1.81x
Total Equity+	2.01B	2.14B	2.43B	2.54B	2.98B	3.34B	3.75B	4.02B	4.44B	4.28B
Equity Growth %	0.05%	0.06%	0.14%	0.05%	0.17%	0.12%	0.13%	0.07%	0.1%	-0.04%
Book Value per Share	41.85	44.90	52.09	54.27	63.27	70.56	79.17	85.01	93.88	90.84
Total Shareholders' Equity	2.01B	2.14B	2.43B	2.54B	2.98B	3.34B	3.75B	4.02B	4.44B	4.28B
Common Stock	43.52M	45.81M	46.87M	47.25M	47.54M	47.81M	47.93M	47.96M	48.05M	48.1M
Retained Earnings	2.02B	2.19B	2.29B	2.43B	2.82B	3.1B	3.52B	3.82B	4.11B	4.12B
Treasury Stock	-119.42M	-170.97M	-228.86M	-168.54M	-165.72M	-162.59M	-157.27M	-154.89M	-152.1M	-350.34M
Accumulated OCI	-371.12M	-438.72M	-265.09M	-341.08M	-344.39M	-297.3M	-346.96M	-403.52M	-314.4M	-316.67M
Minority Interest	1.82M	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	300.81M	408.48M	419.88M	437.38M	439.52M	436.41M	651.42M	342.14M	510.64M	635.74M
Operating CF Margin %	0.17%	0.22%	0.2%	0.18%	0.17%	0.17%	0.23%	0.12%	0.17%	0.21%
Operating CF Growth %	0.05%	0.36%	0.03%	0.04%	0%	-0.01%	0.49%	-0.47%	0.49%	0.24%
Net Income	245.71M	237.84M	152.53M	200.8M	461.47M	335.32M	485.37M	363.14M	356.33M	69.67M
Depreciation & Amortization	108.39M	117.91M	155.26M	209.98M	214.06M	227.25M	237.36M	230.59M	242.12M	274.6M
Stock-Based Compensation	14.47M	16.87M	19.41M	22.44M	26.94M	20.74M	22.94M	27.22M	31.46M	31.35M
Deferred Taxes	-54.41M	-29.35M	-41.82M	-6.1M	-168.59M	-32.67M	-110.24M	-13.01M	-13.05M	0
Other Non-Cash Items	-9.9M	46.63M	2.53M	54.55M	20.15M	-136.51M	-111.36M	-25.84M	5.54M	261.94M
Working Capital Changes	-3.44M	18.57M	131.97M	-44.3M	-114.5M	22.28M	127.34M	-239.96M	-111.77M	-1.82M
Change in Receivables	398K	-11.03M	-11.04M	-23.41M	-59.79M	44.75M	-600K	-38.46M	-15.76M	-27.95M
Change in Inventory	-8.37M	6.41M	-22.36M	-37.2M	-53.17M	-5.5M	-11.14M	-110.69M	-41.07M	1.72M
Change in Payables	-117K	15.42M	39M	52.05M	5M	-3.68M	94.02M	-24.79M	-31.26M	9.66M
Cash from Investing+	-154.85M	-56.97M	-1.83B	-196.39M	-73.48M	-837.78M	156.74M	-257.94M	-621.23M	-99.36M
Capital Expenditures	-61.45M	-53.13M	-70.9M	-80.8M	-102.69M	-90.69M	-71.62M	-79.19M	-91.44M	-126.43M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.04%	0.04%	0.03%	0.03%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	408K	10.2M	6.33M	1.55M	18.33M	19.34M	19.15M	22.24M	63.13M	27.2M
Cash from Financing+	-85.58M	-118.69M	1.14B	-206.43M	-418.84M	455.16M	-715.82M	-217.51M	38.54M	-421.93M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-56.53M	-58.96M	-61.24M	-62.16M	-62.83M	-63.22M	-63.65M	-63.79M	-63.9M	-63.54M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-13.39M	-16.87M	-21.43M	-50.77M	-102.51M	-56.62M	-28.77M	-8.27M	1.19M	3.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	239.36M	355.35M	348.98M	356.58M	336.83M	345.71M	579.8M	262.95M	419.2M	509.31M
FCF Margin %	0.13%	0.19%	0.16%	0.15%	0.13%	0.14%	0.21%	0.09%	0.14%	0.17%
FCF Growth %	0.09%	0.48%	-0.02%	0.02%	-0.06%	0.03%	0.68%	-0.55%	0.59%	0.21%
FCF per Share	4.98	7.46	7.48	7.62	7.15	7.31	12.23	5.56	8.86	10.81
FCF Conversion (FCF/Net Income)	1.23x	1.72x	2.75x	2.18x	0.95x	1.30x	1.34x	0.94x	1.43x	9.12x
Interest Paid	45.97M	44.2M	74.26M	101.79M	0	0	73.6M	70.92M	100.22M	98.38M
Taxes Paid	56.08M	23.95M	49.14M	65.61M	0	0	108.61M	162.05M	114.21M	164.9M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	12.48%	11.44%	6.68%	8.08%	16.72%	10.62%	13.69%	9.34%	8.42%	1.6%
Return on Invested Capital (ROIC)	8.75%	8.93%	8.01%	5.55%	7.1%	6.21%	8.72%	6.92%	6.49%	1.91%
Gross Margin	52.19%	53.33%	54.6%	56.55%	54.29%	52.22%	55.15%	54.86%	55.37%	55.87%
Net Margin	13.53%	12.71%	7.11%	8.2%	17.78%	13.22%	17.28%	13.01%	11.98%	2.29%
Debt / Equity	0.53x	0.48x	0.93x	0.85x	0.67x	0.77x	0.52x	0.46x	0.43x	0.41x
Interest Coverage	5.15x	5.81x	4.51x	3.12x	5.32x	6.36x	11.03x	9.21x	5.95x	1.81x
FCF Conversion	1.23x	1.72x	2.75x	2.18x	0.95x	1.30x	1.34x	0.94x	1.43x	9.12x
Revenue Growth	-1.64%	3.22%	14.9%	14.07%	6%	-2.24%	10.74%	-0.66%	6.57%	2.45%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Vascular Access	-	-	-	575.33M	600.87M	657.7M	700.24M	683.61M	708.04M	732.67M
Vascular Access Growth	-	-	-	-	4.44%	9.46%	6.47%	-2.37%	3.57%	3.48%
Interventional	-	-	-	395.42M	427.56M	382.44M	427.5M	445.02M	511.43M	586.06M
Interventional Growth	-	-	-	-	8.13%	-10.55%	11.78%	4.10%	14.92%	14.59%
Surgical	-	-	-	358.71M	370.07M	317.2M	377.76M	392.92M	427.36M	450.48M
Surgical Growth	-	-	-	-	3.17%	-14.29%	19.09%	4.01%	8.77%	5.41%
Anesthesia	-	-	-	349.37M	338.41M	302.29M	380.14M	388.89M	389.96M	395.29M
Anesthesia Growth	-	-	-	-	-3.14%	-10.67%	25.75%	2.30%	0.27%	1.37%
Interventional Urology	-	-	-	196.74M	290.45M	290.02M	341.66M	322.83M	319.79M	331.09M
Interventional Urology Growth	-	-	-	-	47.63%	-0.15%	17.81%	-5.51%	-0.94%	3.54%
Other	218.66M	225.21M	233.98M	366.85M	347.27M	367.26M	336.58M	285.15M	291.9M	207.22M
Other Growth	-	3.00%	3.90%	56.79%	-5.34%	5.75%	-8.35%	-15.28%	2.37%	-29.01%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	1.47B	1.66B	1.65B	1.72B	1.89B
Americas Growth	-	-	-	-	-	-	13.26%	-0.34%	3.73%	10.14%
EMEA	514.44M	510.93M	552.72M	603.81M	652.07M	584.86M	606.81M	558.37M	586.25M	705.09M
EMEA Growth	-	-0.68%	8.18%	9.24%	7.99%	-10.31%	3.75%	-7.98%	4.99%	20.27%
Asia	241.73M	249.42M	269.21M	286.89M	241.28M	267.02M	297.77M	306.32M	346.9M	326.37M
Asia Growth	-	3.18%	7.94%	6.57%	-15.90%	10.67%	11.52%	2.87%	13.25%	-5.92%
Oem	149.4M	160.99M	182.97M	205.98M	-	220.25M	245.68M	272.62M	326.01M	-
Oem Growth	-	7.76%	13.65%	12.58%	-	-	11.55%	10.97%	19.58%	-
UNITED STATES	-	-	-	-	1.61B	-	-	-	-	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Teleflex Incorporated (TFX) has a price-to-earnings (P/E) ratio of 70.7x. This suggests investors expect higher future growth.

Growth & Financials

Teleflex Incorporated (TFX) reported $3.19B in revenue for fiscal year 2024. This represents a 109% increase from $1.53B in 2011.

Teleflex Incorporated (TFX) grew revenue by 2.4% over the past year. Growth has been modest.

Teleflex Incorporated (TFX) reported a net loss of $328.0M for fiscal year 2024.

Dividend & Returns

Yes, Teleflex Incorporated (TFX) pays a dividend with a yield of 1.29%. This makes it attractive for income-focused investors.

Teleflex Incorporated (TFX) has a return on equity (ROE) of 1.6%. This is below average, suggesting room for improvement.

Teleflex Incorporated (TFX) generated $264.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.